Insider · CIK 0001759855
James T. Parsons
director
Files at ONCY (ONCOLYTICS BIOTECH INC), DMAC (DiaMedica Therapeutics Inc.). First filing Mar 13, 2026, latest Mar 13, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$10k bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | ONCOLYTICS BIOTECH INC | $10k 10,000 shares | +31% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | ONCY ONCOLYTICS BIOTECH INC | POpen-market purchase Common Shares | +10,000 | $1.03 | $10k | 41,849 | Mar 13, 2026 |
| Jan 2, 2026 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Common Stock | +10,095 | $8.42 | $85k | 97,949 | Jan 6, 2026 |
| Nov 21, 2025 | DMAC DiaMedica Therapeutics Inc. | MOption exercise Common Stock | +12,000 | $2.20 | $26k | 87,854 | Nov 25, 2025 |
| Nov 21, 2025 | DMAC DiaMedica Therapeutics Inc. | MOption exercise Stock Option (right to buy)derivative | -12,000 | $0.00 | $0 | 0 | Nov 25, 2025 |
| Jun 1, 2025 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +40,739 | $0.00 | $0 | 40,739 | Jun 3, 2025 |
| Jan 2, 2025 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Voting Common Shares, no par value per share | +15,917 | $5.34 | $85k | 75,854 | Jan 3, 2025 |
| Jan 2, 2025 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +4,287 | $0.00 | $0 | 4,287 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.